摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(5-Methoxycarbonyl-1,3-oxazol-2-yl)piperazine-1-carboxylic acid

中文名称
——
中文别名
——
英文名称
4-(5-Methoxycarbonyl-1,3-oxazol-2-yl)piperazine-1-carboxylic acid
英文别名
4-(5-methoxycarbonyl-1,3-oxazol-2-yl)piperazine-1-carboxylic acid
4-(5-Methoxycarbonyl-1,3-oxazol-2-yl)piperazine-1-carboxylic acid化学式
CAS
——
化学式
C10H13N3O5
mdl
——
分子量
255.23
InChiKey
GMSAJFRFBZKSBV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.3
  • 重原子数:
    18
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    96.1
  • 氢给体数:
    1
  • 氢受体数:
    7

文献信息

  • NEW COMPOUNDS
    申请人:Proximagen Limited
    公开号:US20150258101A1
    公开(公告)日:2015-09-17
    The present invention provides certain compounds according to formula (I) which are inhibitors of SSAO activity wherein V, W, X, Y, Z, R 1 and R 2 are as defined in the specification.
    本发明提供了一些按照式(I)的化合物,这些化合物是SSAO活性的抑制剂,其中V、W、X、Y、Z、R1和R2如规范中所定义。
  • [EN] NEW THERAPEUTIC USES OF COMPOUNDS<br/>[FR] NOUVELLES UTILISATIONS THÉRAPEUTIQUES DE COMPOSÉS
    申请人:PROXIMAGEN LLC
    公开号:WO2021195406A1
    公开(公告)日:2021-09-30
    The present invention relates to the treatment and prevention of pulmonary inflammation using a compound of Formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, N-oxide, and/or prodrug thereof. The pulmonary inflammation may be associated with acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS), which in turn may be associated with viral induced cytokine surge. Such diseases and conditions may be caused by a coronavirus, i.e., severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2), severe acute respiratory syndrome coronavirus (SARS-CoV), or Middle East respiratory syndrome coronavirus (MERS-CoV). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    本发明涉及使用化合物I式或其药用可接受的盐、溶剂化合物、水合物、N-氧化物和/或前药来治疗和预防肺部炎症。肺部炎症可能与急性肺损伤(ALI)和/或急性呼吸窘迫综合征(ARDS)相关联,而这些可能与病毒引起的细胞因子激增有关。这些疾病和状况可能由冠状病毒引起,即严重急性呼吸综合征冠状病毒2(SARS-CoV-2)、严重急性呼吸综合征冠状病毒(SARS-CoV)或中东呼吸综合征冠状病毒(MERS-CoV)引起。本摘要旨在作为特定领域搜索的扫描工具,不限制本发明。
  • IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS
    申请人:PROXIMAGEN LIMITED
    公开号:US20160046622A1
    公开(公告)日:2016-02-18
    The compounds of formula (I) are inhibitors of semicarbazide-sensitive amine oxidase (SSAO) activity useful in the treatment of inflammation, an inflammatory disease, an immune or an autoimmune disorder, or inhibition of tumour growth.
    式(I)的化合物是半卡巴肼敏感胺氧化酶(SSAO)活性的抑制剂,可用于治疗炎症、炎症性疾病、免疫或自身免疫性疾病,或抑制肿瘤生长。
  • Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors
    申请人:PROXIMAGEN, LLC
    公开号:US10428066B2
    公开(公告)日:2019-10-01
    The compounds of formula (I) are inhibitors of SSAO activity wherein V, W, X, Y, Z, R1 and R2 are as defined in the claims.
    式(I)化合物是 SSAO 活性抑制剂 其中 V、W、X、Y、Z、R1 和 R2 如权利要求中所定义。
  • Compounds
    申请人:PROXIMAGEN, LLC
    公开号:US10590125B2
    公开(公告)日:2020-03-17
    The present invention relates to compounds which are inhibitors of SSAO activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases, immune disorders and the inhibition of tumor growth.
    本发明涉及作为 SSAO 活性抑制剂的化合物。 本发明还涉及包含这些化合物的药物组合物,以及这些化合物在治疗或预防有利于抑制 SSAO 活性的病症(如炎症性疾病、免疫紊乱和抑制肿瘤生长)中的用途。
查看更多